Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access
Nigel S B Rawson · 2025
Read Consequences of Canada’s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access by Nigel S B Rawson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12743471.txt.
Description
Nigel Rawson audits how Canada's drug review and price talks shape patient access in a solo 2025 paper. New drugs must clear a national value review, then a joint price negotiation, then each province's own listing. He counted the rulings from 2020 to 2024 and traced each drug's path to listing or limbo.
Of three hundred forty four rulings, near eighty five percent said yes with strings, most often a steep price cut, while near fifteen percent said no outright. Only three were clean yeses. The value review took a median of about seven months, and the full road to a price outcome ran a median near seventeen months. Asked price cuts hit a median near three quarters off. The author warns the gauntlet delays real access.
Catalog record
| CREATOR | Nigel S B Rawson |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |